Department of Gastroenterology, Juntendo University School of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo, 113-8421, Japan.
Probiotics Research Laboratory, Juntendo University Graduate School of Medicine, Tokyo, Japan.
Dig Dis Sci. 2018 Nov;63(11):2940-2949. doi: 10.1007/s10620-018-5122-4. Epub 2018 May 24.
Recently, problems associated with proton pump inhibitor (PPI) use have begun to surface. PPIs influence the gut microbiota; therefore, PPI use may increase the risk of enteric infections and cause bacterial translocation. In this study, we investigated fecal microbiota composition, fecal organic acid concentrations and pH, and gut bacteria in the blood of the same patients before and after PPI use.
Twenty patients with reflux esophagitis based on endoscopic examination received 8 weeks of treatment with PPIs. To analyze fecal microbiota composition and gut bacteria in blood and organic acid concentrations, 16S and 23S rRNA-targeted quantitative RT-PCR and high-performance liquid chromatography were conducted.
Lactobacillus species were significantly increased at both 4 and 8 weeks after PPI treatment compared with bacterial counts before treatment (P = 0.011 and P = 0.002, respectively). Among Lactobacillus spp., counts of the L. gasseri subgroup, L. fermentum, the L. reuteri subgroup, and the L. ruminis subgroup were significantly increased at 4 and 8 weeks after treatment compared with counts before treatment. Streptococcus species were also significantly increased at 4 and 8 weeks after PPI treatment compared with counts before treatment (P < 0.01 and P < 0.001, respectively). There was no significant difference in the total organic acid concentrations before and after PPI treatment. Detection rates of bacteria in blood before and after PPI treatment were 22 and 28%, respectively, with no significant differences.
Our quantitative RT-PCR results showed that gut dysbiosis was caused by PPI use, corroborating previous results obtained by metagenomic analysis.
最近,与质子泵抑制剂(PPI)使用相关的问题开始显现。PPIs 会影响肠道微生物群;因此,PPI 的使用可能会增加肠内感染的风险,并导致细菌易位。在这项研究中,我们调查了同一批患者在使用 PPI 前后粪便微生物群组成、粪便有机酸浓度和 pH 值以及肠道细菌的变化。
20 例经内镜检查确诊为反流性食管炎的患者接受了 8 周的 PPI 治疗。为了分析粪便微生物群组成和血液中的肠道细菌以及有机酸浓度,我们进行了 16S 和 23S rRNA 靶向定量 RT-PCR 和高效液相色谱分析。
与治疗前相比,PPI 治疗后 4 周和 8 周时乳杆菌属的数量明显增加(P=0.011 和 P=0.002)。在乳杆菌属中,L. gasseri 亚组、L. fermentum、L. reuteri 亚组和 L. ruminis 亚组的数量在治疗后 4 周和 8 周时均明显增加。治疗后 4 周和 8 周时,链球菌属的数量也明显高于治疗前(P<0.01 和 P<0.001)。PPI 治疗前后总有机酸浓度无显著差异。PPI 治疗前后血液中细菌的检出率分别为 22%和 28%,差异无统计学意义。
我们的定量 RT-PCR 结果表明,PPI 的使用导致了肠道菌群失调,与之前的宏基因组分析结果一致。